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Increasing experimental evidence, including recently developed animal models, supports a role for 
homocysteine in the development of chronic kidney disease (CKD). However, relatively few clinical/
epidemiological studies have examined this hypothesis in humans. We examined the relationship 
between plasma homocysteine level and CKD in a population-based study of older Australians. 
METHODS: 
Community-based study (1992-1994) among 2,609 individuals (58.6% women), aged 49-98 years, free of 
clinical cardiovascular disease in the Blue Mountains region, west of Sydney, Australia. The main 
outcome-of-interest was CKD (n = 461), defined as estimated glomerular filtration rate of <60 ml>/min/
1.73 m(2). 
RESULTS: 
Higher plasma homocysteine levels were positively associated with CKD, independent of smoking, body 
mass index, diabetes mellitus, hypertension, cholesterol levels, and other confounders. The multivariable 
odds ratio (OR; 95% confidence intervals, CI) comparing quartile 4 of plasma homocysteine (>14 
micromol/l) to quartile 1 (< or =9 micromol/l) was 10.44 (6.99-15.60), p-trend <0.0001. This association 
persisted in both men and women separately. The results were also consistent in subgroup analyses by 
categories of diabetes mellitus and hypertension. 
CONCLUSIONS: 
Higher plasma homocysteine levels are associated with CKD in a community-based sample of older 
Australians. This association appeared to be independent of diabetes mellitus and hypertension. 
Keywords 
between, plasma, homocysteine, level, chronic, association, positive, disease, kidney 
Disciplines 
Education | Social and Behavioral Sciences 
Publication Details 
Shankar, A., Wang, J. Jin., Chua, B., Rochtchina, E., Flood, V. & Mitchell, P. (2008). Positive association 
between plasma homocysteine level and chronic kidney disease. Kidney and Blood Pressure Research, 31 
(1), 55-62. 
Authors 
Anoop Shankar, Jie Wang, Brian Chua, Elena Rochtchina, Victoria Flood, and Paul Mitchell 
This journal article is available at Research Online: https://ro.uow.edu.au/sspapers/973 
Fax +41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com
 Original Paper 
 Kidney Blood Press Res 2008;31:55–62 
 DOI: 10.1159/000114300 
 Positive Association between
Plasma Homocysteine Level and
Chronic Kidney Disease 
 Anoop Shankar a    Jie Jin Wang b    Brian Chua b    Elena Rochtchina b    Vicki Flood b, c  
Paul Mitchell b 
 a  Division of Epidemiology, Department of Community, Occupational, and Family Medicine,
National University of  Singapore , Singapore;  b  Centre for Vision Research, Department of Ophthalmology and
Westmead Millennium Institute, and  c  Human Nutrition Unit, Departments of Molecular and
Microbial Biosciences and School of Public Health, University of Sydney,  Sydney, N.S.W. , Australia 
separately. The results were also consistent in subgroup 
analyses by categories of diabetes mellitus and hyperten-
sion.  Conclusions:  Higher plasma homocysteine levels are 
associated with CKD in a community-based sample of older 
Australians. This association appeared to be independent of 
diabetes mellitus and hypertension. 
 Copyright © 2008 S. Karger AG, Basel 
 Introduction 
 End-stage renal disease (ESRD) is an important public 
health problem. There were estimated to be approximate-
ly 470,000 patients with ESRD in the United States in 
2004  [1] , and based on earlier data an estimated addition-
al 8 million US adults have chronic kidney disease (CKD), 
defined as a glomerular filtration rate (GFR) of  ! 60 ml/
min/1.73 m 2 , who are at risk of progression to ESRD and 
its attendant complications [2, 3] . It is therefore impor-
tant to identify factors related to CKD, a kidney disease 
stage earlier in the continuum at which prevention/con-
trol of disease progression is more applicable.
 Key Words 
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 Abstract 
 Background: Increasing experimental evidence, including 
recently developed animal models, supports a role for ho-
mocysteine in the development of chronic kidney disease 
(CKD). However, relatively few clinical/epidemiological stud-
ies have examined this hypothesis in humans. We examined 
the relationship between plasma homocysteine level and 
CKD in a population-based study of older Australians.
 Methods:  Community-based study (1992–1994) among 
2,609 individuals (58.6% women), aged 49–98 years, free of 
clinical cardiovascular disease in the Blue Mountains region, 
west of Sydney, Australia. The main outcome-of-interest was 
CKD (n = 461), defined as estimated glomerular filtration rate 
of  ! 60 ml/min/1.73 m 2 .  Results: Higher plasma homocys-
teine levels were positively associated with CKD, indepen-
dent of smoking, body mass index, diabetes mellitus, hy-
pertension, cholesterol levels, and other confounders. The 
multivariable odds ratio (OR; 95% confidence intervals, CI) 
comparing quartile 4 of plasma homocysteine ( 1 14   mol/l) 
to quartile 1 ( ̂  9   mol/l) was 10.44 (6.99–15.60), p-trend 
 ! 0.0001. This association persisted in both men and women 
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 Homocysteine is a sulfur-containing amino acid 
formed during the metabolism of the essential amino 
acid methionine [4] . Previous epidemiologic studies have 
reported an association between plasma homocysteine 
levels and atherosclerotic vascular disease [4–6] , shown 
to be a predictor of subsequent CKD [7] . Studies have also 
reported an association between plasma homocysteine 
and hypertension [8, 9] , another strong, independent pre-
dictor of CKD [10] . Homocysteine may directly cause re-
nal vascular damage through the production of reactive 
oxygen species, effects on vascular smooth muscle cells, 
endothelial injury, reduction in plasma and tissue inter-
stitium adenosine levels, and mesangial cell proliferation 
and apoptosis [4, 11–16] . Experimental animal models of 
homocysteine-induced glomerular damage have also 
been developed [14, 17] . However, few studies have exam-
ined the putative association between elevated plasma 
homocysteine and CKD [18–20] . While one large study 
reported a positive association between homocysteine 
and CKD in a Japanese population sample [18] , two ear-
lier studies did not find an independent association [19, 
20] . In particular, it is not clear if plasma homocysteine is 
related to CKD independent of hypertension and diabe-
tes mellitus, two of its strong predictors. In this context, 
we examined the association between plasma homocys-
teine levels and CKD in a population-based sample of 
older Australian adults after adjusting for the major con-
founders and stratifying by hypertension and diabetes 
mellitus status.
 Methods 
 The current report is based on the second Blue Mountains Eye 
Study (BMES II, 1997–2000), a population-based study of par-
ticipants aged  6 49 years, living in two postcodes of the Blue 
Mountains region, west of Sydney, Australia, which has studied 
age-related eye diseases and other health outcomes in an older 
urban Australian population. Details of the study methods have 
previously been described [21] . In brief, this cross-sectional sur-
vey (BMES II, 1997–2000) consisted of 3,509 participants. It in-
cluded 2,335 participants (75.1% survivors from the baseline sur-
vey, BMES I, 1992–1994) plus an additional 1,174 participants 
(identified in a repeat door-to-door census, 1999–2000) who had 
become eligible by moving into the area or into the age bracket of 
the original survey. The Blue Mountains population is representa-
tive of the Australian population. This study followed the recom-
mendations of the Declaration of Helsinki, was approved by the 
Western Sydney Area Health Service Human Research Ethics 
Committee, and written, informed consent was obtained from all 
participants.
 The examination protocols involved measurement of weight, 
height, systolic and diastolic blood pressures by a trained inter-
viewer, and administration of a standardized questionnaire col-
lecting information regarding demographic characteristics, ciga-
rette smoking, alcohol intake, physical activity, and past medical 
history.
 Fasting blood specimens were drawn from 2,961 participants 
(84.4%), centrifuged onsite and then couriered the same day to 
Westmead Hospital, Sydney, Australia, for hematology and clini-
cal biochemistry assessment. Plasma total homocysteine was de-
termined using the fluorescent polarization immunoassay meth-
od on an IMx Analyzer. This system correlates well with HPLC 
and gas chromatography-mass spectrometry assay methods [22] . 
Serum folate and vitamin B 12 assays were performed using the 
competitive-binding assay method on a Beckman-Access analyz-
er. White blood cell (WBC) count was determined using a Coulter 
counter method. Total cholesterol, high-density lipoprotein cho-
lesterol and triglyceride were measured on a Reflotron reflectance 
photometric analyzer (Boehringer Mannheim Diagnostics [cur-
rently Roche Diagnostics], Germany). Fasting plasma glucose was 
measured using the hexokinase method.
 Age was defined as age at the baseline examination; education 
was categorized into beyond high school, high school, and below 
high school, and body mass index (BMI) was calculated as weight 
(kg) divided by height squared (m 2 ). Diabetes status was catego-
rized using the American Diabetes Association criteria as follows: 
diabetes = diagnosis by a physician and use of diabetic medica-
tions or fasting glucose levels at least 7.0 mmol/l (126 mg/dl); fast-
ing hyperglycemia = fasting glucose levels 6.1 mmol/l (110 mg/dl) 
or above but less than 7.0 mmol/l (126 mg/dl), and normoglyce-
mia = fasting glucose levels below 6.1 mmol/l (110mg/dl). Ciga-
rette smoking was categorized into current (current smoker or had 
stopped smoking  ! 12 months before the study examination), for-
mer (positively answered to ‘have you ever smoked regularly be-
fore?’ and had stopped smoking at least 12 months before the study 
examination), and never smoker. Alcohol intake was categorized 
as nondrinker,  ! once/week, 1–6 days/week, 1–2 drinks/day, 3 or 
more drinks/day, and don’t know/missing. Physical inactivity (yes, 
no) was categorized as answering negatively to ‘have you partici-
pated in any recreational exercise/walk in the last 2 weeks?’.
 Details of blood pressure measurement and prevalence of hy-
pertension in this older Australian community have been de-
scribed previously [23] . Briefly, systolic and diastolic blood pres-
sure was recorded by trained observers from the right arm with a 
mercury sphygmomanometer using a cuff size appropriate for the 
participant’s arm circumference, after they had been comfortably 
seated for at least 10 min. Hypertension was defined according to 
the Seventh Report of the Joint National Committee on Preven-
tion, Detection, Evaluation, and Treatment of High Blood Pres-
sure as a systolic blood pressure of 140 mm Hg or higher, diastol-
ic blood pressure 90 mm Hg or higher, or a combination of self-
reported hypertension diagnosis and use of antihypertensive 
medications [24] .
 Estimated GFR (eGFR) was the preferred measure of kidney 
function in the current study. GFR was indirectly estimated using 
the 4-variable Modification of Diet in Renal Disease Study equa-
tion [25] . The main outcome of interest was CKD, defined as an 
eGFR of  ! 60 ml/min/1.73 m 2 , consistent with the National Kid-
ney Foundation Kidney Disease Outcomes Quality Initiative 
 6 stage 2 chronic kidney disease [2] .
 To examine the association between plasma homocysteine 
and hypertension and CKD of the 2,961 individuals who partici-
pated in the survey and had plasma homocysteine measured, the 
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current study included 2,609 individuals free of clinical cardio-
vascular disease (1,080 men and 1,529 women) after excluding 
those with missing systolic or diastolic blood pressure (n = 23), 
serum creatinine levels (n = 10), and those with preexisting coro-
nary heart disease (n = 223) or stroke (n = 96).
 Statistical Methods 
 Baseline plasma homocysteine was categorized into quartiles 
( ̂  9.9, 10.0–11.9, 12.0–14.9,  1 14.9   mol/l) for the main analyses. 
Homocysteine was also analyzed as a continuous variable (1 SD 
[4.6   mol/l] increase). We used   2 test and analysis of variance to 
compare the relationship of selected baseline characteristics by 
plasma homocysteine quartiles. We were interested in two out-
comes (1) hypertension and (2) CKD. We used multivariable lo-
gistic regression models to determine the odds ratio (OR) and 
95% confidence interval (CI) of hypertension (n = 1,986) and 
CKD (n = 461), controlling for potential confounders. We used 2 
logistic regression models: an age- (years), sex-adjusted model, 
and a multivariable-adjusted model, additionally adjusting for 
smoking (never, former, current), alcohol intake (nondrinker,
 ! 3 drinks/day,  6 3 drinks/day), BMI (kg/m 2 ), physically inactive 
(no, yes), diabetes mellitus (absent, present), hypertension (ab-
sent, present; adjusted in models with CKD as the outcome), mean 
arterial blood pressure (mm Hg; adjusted in models with CKD as 
the  outcome), serum total cholesterol (mmol/l), HDL cholesterol 
(mmol/l), triglyceride (mmol/l); among women we additionally 
adjusted for menopausal status (absent, present), and ever use of 
hormone replacement therapy (no, yes). Logistic regression mod-
els with plasma homocysteine quartiles as ordered categories 
scaled to the median for each quartile were used to assess trends 
in OR. To examine the consistency of the association between ho-
mocysteine and CKD, we performed analyses within subgroups 
of major confounders, including gender (men, women), hyperten-
sion (absent, present), and diabetes mellitus (absent, present). We 
formally evaluated effect modification by including cross-prod-
uct interaction terms in corresponding logistic regression mod-
els. We also performed several supplementary analyses. First, we 
repeated the multivariable model additionally adjusting for serum 
folate and vitamin B 12 to examine if the observed association be-
tween plasma homocysteine and CKD was explained by these mi-
cronutrients. Second, to examine if the observed association be-
tween plasma homocysteine and CKD was explained by inflam-
mation, we repeated the multivariable model additionally adjusting 
for WBC count, a nonspecific marker of inflammation available 
in the current study. SAS version 9.2 was used for all analyses.
 Results 
 Among the 2,609 adults aged  6 49 years without clin-
ical cardiovascular disease who were included in the cur-
rent analysis, 1,986 subjects had hypertension and 461 
had CKD.  Table 1 presents the characteristics of the study 
population by plasma homocysteine quartiles. Subjects 
Table 1. Baseline characteristics of the cohort by quartiles of plasma homocysteine
Characteristics Quartile of plasma homocysteine (mol/l) p value
quartile 1 quartile 2 quartile 3 quartile 4
≤9.9 mol/l 10.0–11.9 mol/l 12.0–14.9 mol/l >14.9 mol/l
Age, years 62.280.3 65.380.3 67.580.4 70.980.3 <0.0001
Women, % 73.5 56.4 52.6 47.1 <0.0001
Smoking
Current smoker, % 9.4 9.0 9.7 9.7 0.97
Former smoker, % 35.7 38.3 40.2 46.7 0.0003
Alcohol use >3 drinks/day, % 11.8 15.7 16.2 18.9 0.003
Body mass index, kg/m2 27.280.2 27.380.2 27.980.2 28.080.2 0.001
Physically inactive, % 16.0 20.4 24.0 29.0 <0.0001
Diabetes mellitus, % 9.0 9.7 10.3 10.6 0.08
Serum total cholesterol, mmol/l 5.880.04 5.880.04 5.980.04 5.980.04 0.04
Serum triglyceride, mmol/l 1.5380.03 1.5380.04 1.5580.04 1.5980.04 0.04
Serum HDL cholesterol, mmol/l 1.5380.01 1.4680.02 1.4780.02 1.4580.02 0.0006
Mean arterial pressure, mm Hg 104.281.1 106.881.2 106.581.4 108.281.2 0.03
Hypertension, % 68.2 77.2 79.7 82.0 <0.0001
eGFR, ml/min/1.73 m2 81.780.6 75.980.7 71.580.8 65.080.7 <0.0001
Chronic kidney disease (%) 4.7 11.7 20.5 37.2 <0.0001
Women only
Menopausal status, % 93.5 95.9 97.3 98.4 0.003
Hormone replacement therapy,% 45.3 41.8 30.5 25.6 <0.0001
The data presented are mean 8 SD values or row percentages. The p values are based on analysis of variance or the 2 test, as ap-
propriate. eGFR = Estimated glomerular filtration rate based on the Modification of Diet in Renal Diseases study equation [25].
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with higher plasma homocysteine levels were more likely 
to be older, former smokers, physically inactive, diabetic, 
hypertensive, to have consumed  1 3 drinks of alcohol/day, 
higher BMI, higher serum total cholesterol and triglycer-
ide levels, lower HDL cholesterol levels, and higher mean 
arterial pressure, and were less likely to be women than 
those with lower plasma homocysteine. The mean eGFR 
decreased and the prevalence of CKD increased with in-
creasing plasma homocysteine quartiles.
 In  table 2 , increasing plasma homocysteine quartiles 
were positively associated with hypertension in both the 
age- and sex-adjusted and multivariable-adjusted mod-
els; models evaluating trend in this association were also 
statistically significant. When plasma homocysteine was 
analyzed as a continuous variable (per SD increase) the 
positive association with hypertension persisted. Also in 
a related subsidiary analysis (data not shown in tables), 
we confirmed that hypertension was positively associated 
with CKD in the current study sample (multivariable OR 
1.98, 95% CI 1.12–3.50).
 Table 3 presents the OR of CKD by increasing plasma 
homocysteine quartiles. Increasing plasma homocyste-
ine quartiles were strongly positively associated with 
CKD. When plasma homocysteine was analyzed as a con-
Table 2. Association between quartiles of plasma homocysteine and hypertension








Whole cohort (n = 2,609)
Quartile 1 (≤9.9 mol/l) 802 547 1 (referent) 1 (referent)
Quartile 2 (10.0–11.9 mol/l) 658 508 1.41 (1.11–1.80) 1.26 (0.98–1.63)
Quartile 3 (12.0–14.9 mol/l) 487 388 1.46 (1.11–1.94) 1.30 (0.97–1.74)
Quartile 4 (>14.9 mol/l) 662 543 1.48 (1.12–1.96) 1.41 (1.06–1.88)
p-trend 0.0034 0.0178
One SD (4.6 mol/l) increase 2,609 1,986 1.29 (1.19–1.40) 1.23 (1.14–1.32)
OR = Odds ratio; 95% CI = 95% confidence interval.
a Estimated from a logistic regression model adjusted for age 
(years), sex, smoking (never, former, current), alcohol intake 
(nondrinker, <3 drinks/day, ≥3 drinks/day), body mass index (kg/
m2), physically inactive (no, yes), diabetes mellitus (absent, pres-
ent), serum total cholesterol (mmol/l), HDL cholesterol (mmol/l), 
triglyceride (mmol/l). Among women we additionally adjusted 
for menopausal status (absent, present), and ever use of hormone 
replacement therapy (yes, no).
Table 3. Association between quartiles of plasma homocysteine and chronic kidney disease (CKD)
Plasma homocysteine quartiles Number
at risk




Whole cohort (n = 2,609)
Quartile 1 (≤9.9 mol/l) 802 38 1 (referent) 1 (referent)
Quartile 2 (10.0–11.9 mol/l) 658 77 2.67 (1.78–3.99) 2.54 (1.66–3.89)
Quartile 3 (12.0–14.9 mol/l) 487 100 5.20 (3.51–7.70) 4.68 (3.07–7.13)
Quartile 4 (>14.9 mol/l) 662 246 11.89 (8.28–17.07) 10.44 (6.99–15.60)
p-trend <0.0001 <0.0001
One SD (4.6 mol/l) increase 2,609 461 2.24 (2.00–2.51) 2.12 (1.89–2.39)
OR = Odds ratio; 95% CI = 95% confidence interval.
aEstimated from a logistic regression model adjusted for age 
(years), sex, smoking (never, former, current), alcohol intake 
(nondrinker, <3 drinks/day, ≥3 drinks/day), body mass index (kg/
m2), physically inactive (no, yes), diabetes mellitus (absent, pres-
ent), hypertension (absent, present), mean arterial blood pressure 
(mm Hg), serum total cholesterol (mmol/l), HDL cholesterol 
(mmol/l), triglyceride (mmol/l). Among women we additionally 
adjusted for menopausal status (absent, present), and ever use of 
hormone replacement therapy (yes, no).
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tinuous variable the positive association with CKD per-
sisted.
 Table 4 shows a clear positive association between 
plasma homocysteine levels and CKD in both men and 
women. Similarly, a consistent positive association was 
observed in subgroup analyses after stratifying by the 
presence of hypertension ( table 5 ) or diabetes mellitus 
( table 6 ).
 We also performed several supplementary analyses. 
First, we repeated the main analysis additionally adjust-
ing for serum folate and vitamin B 12 in the multivariable 
model; the observed association between plasma homo-
cysteine quartiles and CKD remained largely unchanged. 
Compared to quartile 1 of plasma homocysteine, the 
multivariable OR of CKD was 2.87 (95% CI 1.86–4.43) in 
quartile 2; 5.62 (3.63–8.71) in quartile 3, and 13.72 (8.91–
21.13) in quartile 4 (p-trend  ! 0.0001). Second, to exam-
ine if the observed association between plasma homocys-
teine and CKD was explained by inflammation, we re-
peated the multivariable model additionally adjusting for 
WBC count; results remained similar here also. Com-
pared to quartile 1 of plasma homocysteine, the multi-
variable OR of CKD was 2.53 (95% CI 1.65–3.88) in quar-
tile 2; 4.65 (3.05–7.09) in quartile 3, and 10.36 (6.93–15.47) 
in quartile 4 (p-trend  ! 0.0001).
 Discussion 
 Higher plasma homocysteine levels were found to be 
positively associated with CKD in a population-based 
sample of older Australians, free of clinical cardiovascu-
lar disease. This association persisted after adjusting for 
age, sex, BMI, smoking, alcohol intake, diabetes mellitus 
and hypertension, and was consistently present in sub-
group analysis by gender and important confounders. 
The OR for the likely presence of CKD increased in a 
dose-dependent manner with increasing quartiles of 
plasma homocysteine. Our results contribute to the lit-
erature by suggesting that the putative plasma homocys-
teine–CKD association appears to be independent of 
both diabetes mellitus and hypertension. 
 Our finding of a positive association between higher 
plasma homocysteine levels and CKD shows high inter-
nal validity as shown by the magnitude of this associa-
tion, its independence from related factors such as smok-
ing, alcohol intake, BMI, diabetes mellitus, hypertension, 
and serum lipid levels, the presence of a dose-response 
trend, and the consistency of this association in subgroup 
analyses by gender, and other important confounders. 
Also, several lines of recent evidence suggest that an as-
sociation between plasma homocysteine and renal vascu-
lar damage and subsequent CKD is plausible, including a 
Plasma homocysteine quartiles Number
at risk
CKD cases Multivariable OR
(95% CI)a
Men (n = 1,080)
Quartile 1 (≤9.9 mol/l) 212 4 1 (referent)
Quartile 2 (10.0-11.9 mol/l) 287 9 1.22 (0.36–4.19)
Quartile 3 (12.0–14.9 mol/l) 231 16 2.82 (0.90–8.95)
Quartile 4 (>14.9 mol/l) 350 83 8.85 (3.05–25.70)
p-trend <0.0001
Women (n = 1,529)
Quartile 1 (≤9.9 mol/l) 590 34 1 (referent)
Quartile 2 (10.0–11.9 mol/l) 371 68 2.85 (1.81–4.49)
Quartile 3 (12.0–14.9 mol/l) 256 84 5.29 (3.35–8.35)
Quartile 4 (>14.9 mol/l) 312 163 11.12 (6.45–19.17)
p-trend <0.0001
OR = Odds ratio; 95% CI = 95% confidence interval.
a Estimated from a logistic regression model adjusted for age (years), sex, smoking 
(never, former, current), alcohol intake (nondrinker, <3 drinks/day, ≥3 drinks/day), body 
mass index (kg/m2), physically inactive (no, yes), diabetes mellitus (absent, present), hy-
pertension (absent, present), mean arterial blood pressure (mm Hg), serum total choles-
terol (mmol/l), HDL cholesterol (mmol/l), triglyceride (mmol/l). Among women we ad-
ditionally adjusted for menopausal status (absent, present), and ever use of hormone 
replacement therapy (yes, no).
Table 4. Association between quartiles of 
plasma homocysteine and chronic kidney 
disease (CKD) by gender
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Plasma homocysteine quartiles Number
at risk
CKD cases Multivariable OR
(95% CI)a
Normotensives (n = 623)
Quartile 1 (≤9.9 mol/l) 255 4 1 (referent)
Quartile 2 (10.0–11.9 mol/l) 150 13 5.91 (1.79–19.51)
Quartile 3 (12.0–14.9 mol/l) 99 18 15.63 (4.71–51.85)
Quartile 4 (>14.9 mol/l) 119 34 23.16 (7.26–73.90)
p-trend <0.0001
Hypertensives (n = 1,986)
Quartile 1 (≤9.9 mol/l) 547 34 1 (referent)
Quartile 2 (10.0–11.9 mol/l) 508 64 2.17 (1.37–3.44)
Quartile 3 (12.0–14.9 mol/l) 388 82 3.76 (2.38–5.92)
Quartile 4 (>14.9 mol/l) 543 212 9.07 (5.89–13.96)
p-trend <0.0001
OR = Odds ratio; 95% CI = 95% confidence interval.
a Estimated from a logistic regression model adjusted for age (years), sex, smoking 
(never, former, current), alcohol intake (nondrinker, <3 drinks/day, ≥3 drinks/day), body 
mass index (kg/m2), physically inactive (no, yes), diabetes mellitus (absent, present), hy-
pertension (absent, present), mean arterial blood pressure (mm Hg), serum total choles-
terol (mmol/l), HDL cholesterol (mmol/l), triglyceride (mmol/l). Among women we ad-
ditionally adjusted for menopausal status (absent, present), and ever use of hormone 
replacement therapy (yes, no). p-interaction for the cross-product interaction term be-
tween hypertension ! homocysteine quartiles = 0.56.
Table 5. Association between quartiles of 
plasma homocysteine and chronic kidney 
disease (CKD) by hypertension status
Plasma homocysteine quartiles Number
at risk
CKD cases Multivariable OR
(95% CI)a
Subjects without diabetes mellitus (n = 2,353)
Quartile 1 (≤9.9 mol/l) 730 34 1 (referent)
Quartile 2 (10.0–11.9 mol/l) 594 67 2.54 (1.62–3.99)
Quartile 3 (12.0–14.9 mol/l) 437 87 4.62 (2.96–7.21)
Quartile 4 (>14.9 mol/l) 592 209 9.68 (6.33–14.81)
p-trend <0.0001
Subjects with diabetes mellitus (n = 256)
Quartile 1 (≤9.9 mol/l) 72 4 1 (referent)
Quartile 2 (10.0–11.9 mol/l) 64 10 2.70 (0.65–11.27)
Quartile 3 (12.0–14.9 mol/l) 50 13 5.46 (1.38–21.54)
Quartile 4 (>14.9 mol/l) 70 37 23.16 (6.12–87.60)
p-trend <0.0001
OR = Odds ratio; 95% CI = 95% confidence interval.
a Estimated from a logistic regression model adjusted for age (years), sex, smoking 
(never, former, current), alcohol intake (nondrinker, <3 drinks/day, ≥3 drinks/day), body 
mass index (kg/m2), physically inactive (no, yes), diabetes mellitus (absent, present), hy-
pertension (absent, present), mean arterial blood pressure (mm Hg), serum total choles-
terol (mmol/l), HDL cholesterol (mmol/l), triglyceride (mmol/l). Among women we ad-
ditionally adjusted for menopausal status (absent, present), and ever use of hormone 
replacement therapy (yes, no). p-interaction for the cross-product interaction term be-
tween diabetes ! homocysteine quartiles = 0.22.
Table 6. Association between quartiles of 
plasma homocysteine and chronic kidney 
disease (CKD) by diabetes status
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role of homocysteine in the production of reactive oxygen 
species, effects on vascular smooth muscle cells, endothe-
lial injury, reduction in plasma and tissue interstitium 
adenosine levels, and mesangial cell proliferation and 
apoptosis [4, 11–16] . Furthermore, experimental animal 
models of homocysteine-induced glomerular damage 
have recently been developed [14, 17] .
 However, relatively few epidemiological studies to date 
have examined the putative association between plasma 
homocysteine levels and CKD [18–20] , and several im-
portant questions regarding this association need further 
clarification. First, while one large study reported a posi-
tive association between homocysteine and CKD [18] , 
two earlier studies did not confirm this association among 
those without diabetes  [19, 20] . In the current study, the 
association between plasma homocysteine and CKD was 
present both among those with or without diabetes mel-
litus, suggesting an association independent of diabetes. 
Second, hypertension is a strong, independent predictor 
of CKD [10] . As plasma homocysteine is related to hyper-
tension in the current study ( table 2 ) as well as in previous 
reports [8, 9] , confounding by hypertension/high blood 
pressure needs to be considered in the observed associa-
tion with CKD. In the current study, the homocysteine–
CKD association appeared to be independent of hyper-
tension based on results in the stratified analysis, and was 
present even after adjusting for mean arterial pressure in 
the multivariable model.
 The main advantages of our study include its large 
sample size, stable general population sample base, avail-
ability of rich covariate/confounder information, and the 
use of standardized protocols for exposure and outcome 
assessment. The main study limitation is the cross-sec-
tional nature of the current study which precludes con-
clusions regarding the temporal nature of the association 
between plasma homocysteine and CKD. It is possible 
that at least part of the observed association is due to re-
verse causality, including plasma homocysteine eleva-
tions secondary to reduced renal clearance, and to dis-
ruptions in the normal extrarenal homocysteine metabo-
lism involving unidentified uremic inhibitory substances 
[26] . Also, blood pressure levels were based on a single 
reading in the survey. This could have resulted in slight 
misclassification of hypertension status (likely to be over-
estimation). However, since we also adjusted for mean 
arterial pressure in the multivariable models, the effect of 
hypertension status misclassification on the homocyste-
ine–CKD association is likely to be minimal.
 In conclusion, higher plasma homocysteine levels were 
found to be positively associated with prevalent CKD in 
a population-based sample of older Australians, free of 
clinical cardiovascular disease. This association appeared 
to be independent of diabetes mellitus and hypertension. 
Future prospective studies are needed to clarify the tem-
poral sequence of this association. As CKD is a predictor 
of cardiovascular disease and mortality [27] , a corollary 
observation in light of our findings is that at least part of 
the reported association between plasma homocysteine 
and cardiovascular disease and mortality [4–6] may be 
mediated by its effect on renal dysfunction.
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